No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

International Journal of Cancer

Volumn 79, Issue 1, 1998, Pages 27-33

  Rozan, Sylvie ^a   Vincent Salomon, Anne ^a   Zafrani, Brigitte ^a   Validire, Pierre ^a   De Cremoux, Patricia ^a   Bernoux, Agnès ^a   Nieruchalski, Myriam ^a   Fourquet, Alain ^a   Clough, Krishna ^a   Dieras, Véronique ^a   Pouillart, Pierre ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; ONCOPROTEIN; PROTEIN P53;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; ONCOGENE C ERB; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CELL DIVISION; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; LYMPHATIC METASTASIS; PROGNOSIS; RECEPTOR, ERBB-2; REGRESSION ANALYSIS; S PHASE; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032548879     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980220)79:1<27::AID-IJC6>3.0.CO;2-Y     Document Type: Article

References (31)

1. ALLRED, D.C., CLARK, G.M., TANDON, A.K., MOLINA, R., TORMEY, D.C., OSBORNE, C.K., GILCHRIST, K.W., MANSOUR, E.G., ABELOFF, M., EUDEY, L. and MCGUIRE, W.L., Her-2/neu in node-negative breast cancer: prognostic significance of over-expression influenced by the presence of in situ carcinoma. J. clin. Oncol., 10, 599-605 (1992).
2. BARBARESCHI, M., Prognostic value of the immunohistochemical expression of p53 in breast carcinomas. Appl. Immunohistochem., 4, 106-116 (1996).
3. BERGH, J., NORBERG, T., SJÖGREN, S., LINDGREN, A. and HOLMBERG, L., Complete sequencing of the p53 gene provides prognostic information in breast-cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nature Med., 1, 1029-1034 (1995).
4. CAPRI, G., MEZZLANI, A., VALAGUSSA, P., GRECO, M., BERTUZZI, A., GRASSELI, G., TARENZI, G., MOLITERNI, A., PILOTTI, S. and BONADONNA, G., HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. ASCO 16, 139a (1997).
5. CARLOMAGNO, C., PERRONE, F., GALLO, C., DE LAURENTIIS, M., LAURIA, R., MORABITO, A., PETTINATO, G., PANICO, L., D' ANTONIO, A., BIANCO, A.R. and DE PLACIDO, S., c-erbB2 over-expression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary-lymphnode metastases. J. clin. Oncol., 14, 2702-2708 (1996).
6. DETTMAR, P., HARBECK, N., THOMSSEN, C., PACHE, L., ZIFFER, P., FIZI, K., JANICKE, F., NATHRATH, W., SCHMITT, M., GRAEFF, H. and HOFLER, H., Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Brit. J. Cancer, 75, 1525-1533 (1997).
7. DOMAGALA, W., HAREZGA, B., SZADOWSKA, A., MARKIEWSKI, M., WEBER, K. and OSBORN, M., Nuclear p53 protein accumulates preferentially in medullary and high-grade but rarely in lobular breast carcinomas. Amer. J. Pathol., 142, 669-674 (1993).
8. FAILLE, A., DE CREMOUX, P., EXTRA, J. M., LINARES, G., ESPIE, M., BOURSTYN, E., ROCQUANCOURT, A.D., GIACCHETTI, S., MARTY, M. and CALVO, F., p53 mutations and over-expression in locally advanced breast cancers. Brit. J. Cancer, 69, 1145-1150 (1994).
9. FRASSOLDATI, A., ADAMI, F., BANZI, C., CRISCUOLO, M., PICCININI, M. and SILINGARDI, V., Changes of biological features in breast-cancer cells determined by primary chemotherapy. Breast Cancer Res. Treat., 44, 185-192 (1997).
10. GUSTERSON, B.A. and 20 OTHERS, Prognostic importance of c-erbB-2 expression in breast cancer. J. clin. Oncol., 10, 1049-1056 (1992).
11. HAERSLEV, T., JACOBSEN, G.K. and ZEDELER, K., Correlation of growth fraction by Ki-67 and proliferating-cell-nuclear-antigen(PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res. Treat., 37, 101-113 (1996).
12. JANSSON, T., INGANÄS, M., SJÖGREN, S., NORBERG, T., LINDGREN, A., HOLMBERG, L. and BERGH, J., p53 status predicts survival in breast-cancer patients treated with or without post-operative radiotherapy: a novel hypothesis based on clinical findings. J. clin. Oncol., 13, 2745-2751 (1995).
13. KESHGEGIAN, A. and CNAAN, A., Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating-cell nuclear antigen, Ki-67 and MIB-1. Amer. J. clin. Pathol., 104, 42-49 (1995).
14. LOWE, S.W., BODIS, S., MCCLATCHEY, A., REMINGTON, L., RULEY, E.H., FISHER, D.E., HOUSMAN, D.E. and JACKS, T., p53 status and the efficacy of cancer therapy in vivo. Science, 226, 807-810 (1994).
15. MAKRIS, A., POWLES, T.J., DOWSETT, M and ALLRED, C., p53 protein over-expression and chemosensitivity in breast cancer. Lancet, 345, 1181-1182 (1995).
16. MATHIEU, M.-C, KOSCEILNY, S., LE BIHAN, M.L., SPIELMAN, M. and ARRIAGADA, R., p53 protein over-expression and chemosensitivity in breast cancer. Lancet, 345, 1182 (1995).
17. MUSS, H.B., THOR, A.D., BERRY, D.A., KUTL, T., LAV, E.T., KOERNER, F., CARRINCIONE, C.T., BUDMAN, D.R., WOOD, W.C., BARCOS, M. and HENDERSON, C.I., c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl. J. Med., 330, 1260-1266 (1994).
18. O'CONNOR, P.M., JACKMAN, J., JONDLE, D., BHATIA, K., MAGRATH, I. and KOHN, K.W., Role of the p53 tumor-suppressor gene in cell-cycle arrest and radiosensitivity of Burkitt's-lymphoma cell lines. Cancer Res., 53, 4776-4780 (1993).
19. PORTER, P.L., GARCIA, R., MOE, R., CORWIN, D. and GOWN, A.M., c-erbB-2-oncogene protein in in situ and invasive lobular breast neoplasia. Cancer, 68, 331-334 (1991).
20. REMVIKOS, Y., BEUZEBOC, P., ZAJDELA, A., VOILLEMOT, N., MAGDELENAT, H. and POUILLART, P., Correlation of pre-treatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J. nat. Cancer Inst., 81, 1383-1387 (1989).
21. REMVIKOS, Y., VIEHL, P., PADOY, E., BENYAHIA, B., VOILLEMMOT, N. and MAGDELENAT, H., Breast-cancer proliferation measured on cytological samples: a study by flow cytometry of S-phase fractions and BrdU incorporation. Brit. J. Cancer, 64, 501-507 (1991).
22. ROSEN, P.P., LESSER, M.L., ARROYO, C.D., CRANOR, M., BORGEN, P. and NORTON, L., Immunohistochemical detection of HER2/neu in patients with axillary-lmph-node-negative breast carcinoma. Cancer, 75, 1320-1326 (1994).
23. RUSH, V., KLIMSTRA, D., VENKATRAMAN, E., OLIVER, J., MARTINI, N., GRALLA, R., KRIS, M. and DMITROVSKI, E., Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small-cell lung cancer. Cancer Res., 55, 5038-5042 (1995).
24. SASTRE-GARAU, X., JOUVE, M., ASSELAIN, B., VINCENT-SALOMON, A., BEUZEBOC, P., DORVAL, T., DURAND, J.C., FOURQUET, A. and POUILLART, P., Infiltrating lobular carcinoma of the breast. Clinicopathological analysis of 975 cases with reference to data on conservative therapy and metastatic pattern. Cancer, 77, 113-120 (1996).
25. SCHOLL, S.M. and 13 OTHERS, Neo-adjuvant versus adjuvant chemotherapy in pre-menopausal patients with tumours considered too large for breast-conserving surgery: preliminary results of a randomised trial: S6. Europ. J. Cancer, 30A, 645-652 (1994).
26. SEIDMAN, A., BASELGA, J., YAO, T.-J., GILEWSKI, T., ROSEN, P. and NORTON, L., HER2-new over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. 15, 104 (1996).
27. SESHADRI, R., LEONG, A.S.Y., CAUL, K.M., FIRGAIRA, F.A., SETLUR, V. and HORSFALL, D.J., Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int. J. Cancer (Pred. Oncol.), 69, 135-141 (1996).
28. SILVESTRINI, R., VENERONI, S., BENINI, E., DAIDONE, M.G., LUISI, A., LEUTNER, M., MAUCIONE, A., KENDA, R., ZUCALI, R. and VERONESI, U., Expression of p53, glutathione S-transferase-p and bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer. J. nat. Cancer Inst., 89, 639-645 (1997).
29. SMITH, D.R., JI, C.-Y. and GOH, H.-S., Prognostic significance of p53 over-expression and mutation in colorectal adenocarcinomas. Brit. J. Cancer, 74, 216-223 (1996).
30. STAL, O., SULLIVAN, S., WINGREN, S., SKOOG, L., RUTQVIST, L.E., CARSTENSEN, J.M. and NORDENSKJÖLD, B., C-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Europ. J. Cancer, 31A, 2185-2190 (1995).
31. VERONESE, S.M., MAISANO, C. and SCIBILIA, J., Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res., 16, 2717-2722 (1996).